EDGAR Filing Documents for 0001654954-18-000646

Form 8-K - Current report:

SEC Accession No. 0001654954-18-000646

Filing Date

2018-01-23

Accepted

2018-01-23 14:52:30

Documents

Period of Report

2018-01-22

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	CURRENT REPORT	gtbp_8k.htm	8-K	41090
2	SECURITIES PURCHASE AGREEMENT	gtbp_ex101.htm	EX-10.1	509755
3	REGISTRATION RIGHTS AGREEMENT	gtbp_ex102.htm	EX-10.2	229088
4	FORM OF NOTE	gtbp_ex103.htm	EX-10.3	257847
5	FORM OF WARRANT	gtbp_ex104.htm	EX-10.4	160416
6	PRESS RELEASE	gtbp_ex991.htm	EX-99.2	8938
	Complete submission text file	0001654954-18-000646.txt		1208625

Mailing Address 1825 K STREET SUITE 510 WASHINGTON, D.C. DC 33602

Business Address 1825 K STREET SUITE 510 WASHINGTON, D.C. DC 33602 (800) 304-9888

GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)